145 related articles for article (PubMed ID: 26506079)
1. Impact of number of [(18)F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer.
Miyata H; Yamasaki M; Makino T; Tatsumi M; Miyazaki Y; Takahashi T; Kurokawa Y; Takiguchi S; Mori M; Doki Y
Br J Surg; 2016 Jan; 103(1):97-104. PubMed ID: 26506079
[TBL] [Abstract][Full Text] [Related]
2. Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer.
Miyata H; Yamasaki M; Takahashi T; Murakami K; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Br J Surg; 2013 Oct; 100(11):1490-7. PubMed ID: 24037571
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
[TBL] [Abstract][Full Text] [Related]
5. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
[TBL] [Abstract][Full Text] [Related]
6. Systemic control and evaluation of the response to neoadjuvant chemotherapy in resectable thoracic esophageal squamous cell carcinoma with ¹⁸F-fluorodeoxyglucose positron emission tomography-positive lymph nodes.
Yasuda T; Yano M; Miyata H; Yamasaki M; Higuchi I; Takiguchi S; Fujiwara Y; Doki Y
Surg Today; 2015 Mar; 45(3):335-45. PubMed ID: 24969049
[TBL] [Abstract][Full Text] [Related]
7. The impact of ¹⁸F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma.
Yasuda T; Higuchi I; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Hatazawa J; Doki Y
Ann Surg Oncol; 2012 Feb; 19(2):652-60. PubMed ID: 21769466
[TBL] [Abstract][Full Text] [Related]
8. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
[TBL] [Abstract][Full Text] [Related]
9. Association between prognosis and lymph node status using
Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
World J Surg; 2024 Mar; 48(3):650-661. PubMed ID: 38686781
[TBL] [Abstract][Full Text] [Related]
10. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
Makino T; Doki Y; Miyata H; Yasuda T; Yamasaki M; Fujiwara Y; Takiguchi S; Higuchi I; Hatazawa J; Monden M
Surgery; 2008 Nov; 144(5):793-802. PubMed ID: 19081023
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
[TBL] [Abstract][Full Text] [Related]
12. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of
Hamai Y; Hihara J; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Aoki Y; Furukawa T; Okada M
Ann Surg Oncol; 2019 Jun; 26(6):1869-1878. PubMed ID: 30675704
[TBL] [Abstract][Full Text] [Related]
14. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
Gillies RS; Middleton MR; Han C; Marshall RE; Maynard ND; Bradley KM; Gleeson FV
Br J Surg; 2012 Feb; 99(2):239-45. PubMed ID: 22329010
[TBL] [Abstract][Full Text] [Related]
15. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
16. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI
Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of ¹⁸F-fluorodeoxyglucose positron emission tomography in superficial esophageal squamous cell carcinoma.
Kita Y; Okumura H; Uchikado Y; Sasaki K; Omoto I; Matsumoto M; Setoyama T; Tanoue K; Mori S; Owaki T; Ishigami S; Ueno S; Kajiya Y; Natsugoe S
Ann Surg Oncol; 2013 May; 20(5):1646-52. PubMed ID: 23238695
[TBL] [Abstract][Full Text] [Related]
20. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
